<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200352</url>
  </required_header>
  <id_info>
    <org_study_id>TV50717-CNS-30081</org_study_id>
    <secondary_id>2019-001807-19</secondary_id>
    <nct_id>NCT04200352</nct_id>
  </id_info>
  <brief_title>A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy</brief_title>
  <official_title>An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study TV50717-CNS-30081 is a 55-week study in which patients who have successfully completed
      the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study.

      The primary objective of this study is to evaluate the safety and tolerability of long-term
      therapy with TEV-50717 in children and adolescents with DCP.

      The secondary objective of this study is to evaluate the efficacy of long-term therapy with
      TEV-50717 in reducing the severity of DCP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">April 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 55 weeks</time_frame>
    <description>Adverse events include clinically significant vital signs, ECG parameters, laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>C-SSRS=Columbia-Suicide Severity Rating Scale scores assess suicidal ideation and behaviors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extrapyramidal Symptom Rating Scale</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>Extrapyramidal Symptom Rating Scale (subscales I and II) scores assess four types of movement disorders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Child Behavior Checklist (CBCL)</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>Child Behavior Checklist (for ages 6 to 18) scores assess behavioral and emotional status in children</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>ESS = Epworth Sleepiness Scale (for children and adolescents) scores assess general level of daytime sleepiness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder - Childhood Rating Scale Part I</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>MD-CRS=Movement Disorder- Childhood Rating Scale part I scores provide a general assessment of the movement disorder of motor function (minimum score 0, maximum score 60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder - Childhood Rating Scale Part II</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>MD-CRS=Movement Disorder- Childhood Rating Scale part II scores provide a specific motor assessment of severity of the movement disorder (0 absent, 28 marked dyskinesia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder-Childhood Rating Scale Global Index</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>MD-CRS=Movement Disorder- Childhood Rating Scale Global Index is a child-oriented instrument to describe movement disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Global Impression of Improvement</measure>
    <time_frame>Week 14 to Week 54</time_frame>
    <description>CaGI-I=Caregiver Global Impression of Improvement (global, caregiver rated) scores reflect the impression of improvement in dyskinesia symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement</measure>
    <time_frame>Week 1 to Week 55</time_frame>
    <description>CGI-I=Clinical Global Impression of Improvement (global, physician rated) scores reflect the investigator's assessment of overall improvement in dyskinesia symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity</measure>
    <time_frame>Baseline to Week 54</time_frame>
    <description>CGI-S=Clinical Global Impression of Severity (global, physician rated) scores reflect the investigator's assessment of severity of dyskinesia symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Evaluation Disability Inventory-Computer Adapted Test</measure>
    <time_frame>Baseline to Week 53</time_frame>
    <description>PEDI-CAT (activities of daily living, caregiver completed, content-balanced version) scores reflect the clinical assessment of functional activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Huntington's Disease Rating Scale-Total Motor Score</measure>
    <time_frame>Baseline to Week 53</time_frame>
    <description>UHDRS-TMS=Unified Huntington's Disease Rating Scale-Total Motor Scores reflect the assessment of features associated with Huntington's Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Huntington's Disease Rating Scale-Total Maximal Chorea</measure>
    <time_frame>Baseline to Week 53</time_frame>
    <description>UHDRS-TMC=Unified Huntington's Disease Rating Scale-Total Maximal Chorea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Huntington's Disease Rating Scale-Total Maximal Dystonia</measure>
    <time_frame>Baseline to Week 53</time_frame>
    <description>UHDRS-TMD=Unified Huntington's Disease Rating Scale-Total Maximal Dystonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Canadian Occupational Performance Measure</measure>
    <time_frame>Baseline to Week 53</time_frame>
    <description>COPM=Canadian Occupational Performance Measure assesses patient outcomes in self-care, productivity, and leisure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Cerebral Palsy, Dyskinetic</condition>
  <arm_group>
    <arm_group_label>TEV-50717</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of the TEV-50717 should be increased on a weekly basis to reach a clinically meaningful reduction in dyskinesia, as indicated by a reduction in the Clinical Global Impression of Improvement;(CGI-I).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-50717</intervention_name>
    <description>Oral tablets are 6, 9, and 12 mg.</description>
    <arm_group_label>TEV-50717</arm_group_label>
    <other_name>Deutetrabenazine, SD-809</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Patient has completed parent Study TV50717-CNS-30080.

          -  Patient weighs at least 12 kg (26 lb) on day 1 of this study.

          -  Patient is able to swallow TEV-50717 whole.

          -  NOTE- Additional criteria apply, please contact the investigator for more information

        Exclusion:

          -  Patient has clinically significant depression at screening or day 1 of this study.
             Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose
             for at least 6 weeks before screening or day 1 (whichever comes first) and anticipated
             to remain stable (dose and frequency) within the study duration.

          -  Patient has a history of suicidal intent or related behaviors based on medical or
             psychiatric history or the C-SSRS at screening visit, if performed, or at the day 1
             visit, as applicable according to the patient's age:

               -  intent to act on suicidal ideation with a specific plan, irrespective of level of
                  ambivalence, at the time of suicidal thought

               -  suicidal preparatory acts or behavior.

          -  Patient has a history of a previous actual, interrupted, or aborted suicide attempt.

          -  Patient has a first-degree relative who has completed suicide.

          -  Patient has received any of the following concomitant Patient has received any of the
             following concomitant medications within the specified exclusionary windows from
             screening or day 1 (whichever comes first) of this study:

               -  within 30 days: tetrabenazine or valbenazine

               -  within 21 days: reserpine

               -  within 14 days: levodopa, dopamine agonists, and monoamine oxidase inhibitors

          -  Patient has received treatment with stem cells, deep brain stimulation, transmagnetic
             stimulation, or transcranial direct current stimulation for treatment of abnormal
             movements or CP since the week 15 visit of Study TV50717-CNS-30080, or the patient is
             not in a stable clinical condition.

          -  Patients with a history of torsade de pointes, congenital long QT syndrome,
             bradyarrhythmias, other cardiac arrhythmias, or uncompensated heart failure.

          -  Patient has a known allergy to any of the components of TEV-50717.

          -  Patient has participated in an investigational drug or device study other than Study
             TV50717-CNS-30080 and received IMP/intervention within 30 days or 5 drug half-lives of
             day 1 of this study, whichever is longer.

          -  Patient is pregnant or breastfeeding.

          -  NOTE- Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Pharmaceuticals USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teva U.S. Medical Information</last_name>
    <phone>1-888-483-8279</phone>
    <email>USMedInfo@tevapharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teva Investigational Site 14122</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14299</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30214</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30216</name>
      <address>
        <city>Pisa</city>
        <zip>56018</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53427</name>
      <address>
        <city>Krakow</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53430</name>
      <address>
        <city>Wiazowna</city>
        <zip>05-462</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50475</name>
      <address>
        <city>Khabarovsk</city>
        <zip>680013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50470</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50469</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50478</name>
      <address>
        <city>Stavropol</city>
        <zip>355029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50474</name>
      <address>
        <city>Tyumen</city>
        <zip>625023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31254</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58311</name>
      <address>
        <city>Odessa</city>
        <zip>65012</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58310</name>
      <address>
        <city>Vinnytsa</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34244</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

